Physician profile
Garima Arora
NPI 1407084874
$26,483.19
in general payments reported to CMS, 2019-2025
14 companies · $6,377 in 2025
The $6,377 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,057 · 2021: $1,554 · 2022: $728 · 2023: $14K · 2024: $2,680 · 2025: $6,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $2,115 · Travel and Lodging: $1,904 · Consulting Fee: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,125.00 |
| Food and Beverage | $2,115.07 |
| Travel and Lodging | $1,903.91 |
| Consulting Fee | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $20,317.94 | 2022-2025 | Watchman Access System, Watchman, Watchman Flx |
| Abbott Laboratories | $4,986.51 | 2020-2025 | Mitraclip, Triclip |
| E.R. Squibb & Sons, L.L.C. | $509.59 | 2023-2025 | Camzyos |
| Alnylam Pharmaceuticals INC. | $121.37 | 2024-2025 | Amvuttra |
| Bridgebio Pharma, INC. | $119.36 | 2025 | Attruby |
| Alexion Pharmaceuticals, INC. | $112.29 | 2025 | |
| Edwards Lifesciences Corporation | $65.79 | 2024-2025 | Pascal |
| Astrazeneca Pharmaceuticals LP | $62.95 | 2024-2025 | Wainua |
| Lantheus Medical Imaging, INC. | $47.21 | 2022 | |
| Medtronic, INC. | $44.26 | 2023 | Apollotm |
| Pfizer INC. | $26.95 | 2025 | |
| Ge Healthcare | $24.99 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $24.02 | 2024 | |
| Lilly USA, LLC | $19.96 | 2025 | Amyvid, Kisunla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garima Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.